{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-278835","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.745110+00:00","generated_at":"2026-05-16T20:32:55.583337+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Xilio Q3 net loss $16.3M; cash $103.8M; vilastobart 40% ORR in MSS mCRC subset","bullets":["Net loss $16.3M for Q3 2025 vs $14.0M in Q3 2024; collaboration revenue $19.1M (up from $2.3M YoY).","Cash $103.8M at Sep 30, 2025; plus $17.5M milestone from Gilead in Q4; runway into Q1 2027.","Vilastobart Phase 2 data: 40% ORR in heavily pretreated MSS mCRC without liver metastases and high plasma TMB (≥10 mut/Mb).","Efarindodekin alfa Phase 1 data showed monotherapy activity; RP2D selected; $17.5M milestone from Gilead achieved.","XTX501 IND planned mid-2026; masked T cell engagers advancing with PSMA, CLDN18.2, STEAP1 candidates."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-278835","json":"https://secwatch.observer/filing/0001193125-25-278835.json","markdown":"https://secwatch.observer/filing/0001193125-25-278835.md","text":"https://secwatch.observer/filing/0001193125-25-278835.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525278835/0001193125-25-278835-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525278835/xlo-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:32:55.583337+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}